Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · IEX Real-Time Price · USD
0.574
-0.010 (-1.73%)
Apr 19, 2024, 12:24 PM EDT - Market open
Seres Therapeutics Stock Forecast
MCRB's stock price has decreased by -90.33% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 6.65, with a low estimate of 1.25 and a high estimate of 12. The average target predicts an increase of 1,058.33% from the current stock price of 0.57.
Analyst Consensus: Hold
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for MCRB stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 6 | 6 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +770.93% | Mar 6, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +1,293.49% | Mar 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +1,467.67% | Jan 16, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $4 → $1.25 | Strong Sell | Maintains | $4 → $1.25 | +117.73% | Nov 3, 2023 |
| Oppenheimer | Oppenheimer | Buy Initiates $12 | Buy | Initiates | $12 | +1,990.23% | Jun 26, 2023 |
Financial Forecast
Revenue This Year
1.39M
from 126.33M
Decreased by -98.90%
Revenue Next Year
9.35M
from 1.39M
Increased by 575.16%
EPS This Year
-1.16
from -0.89
EPS Next Year
-0.82
from -1.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.3M | 41.8M | 109.2M | 10.0M | 97.6M |
| Avg | 1.4M | 9.4M | 53.5M | 7.9M | 88.7M |
| Low | n/a | n/a | n/a | 5.9M | 79.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -95.0% | 2,920.1% | 1,067.4% | -81.2% | 1,128.9% |
| Avg | -98.9% | 575.2% | 472.6% | -85.2% | 1,017.1% |
| Low | - | - | - | -89.0% | 899.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.84 | -0.39 | 0.31 | 0.26 | 1.43 |
| Avg | -1.16 | -0.82 | -0.17 | 0.26 | 1.39 |
| Low | -1.54 | -1.43 | -0.64 | 0.25 | 1.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 460.0% |
| Avg | - | - | - | - | 444.0% |
| Low | - | - | - | - | 422.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.